Biomerics Expands Manufacturing Operations In Texas

Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced the completion of a 24,000 sq. ft. expansion of manufacturing operations at their Athens, TX, facility. Driven by growth in the single-use endoscopy market, this investment includes 8,500 sq. ft. of production space and the expansion of Biomerics’ Center of Excellence for Balloons & Balloon Catheters with a 4,900 sq. ft. engineering laboratory adjacent to a CNC-machining (computer numerical control machining) tool shop.

“This expansion reflects our 30-year pursuit of innovation and manufacturing excellence. I’m thrilled to see our vertical integration on full display in one building,” stated Chris Richardson, President of Biomerics Interventional Advanced Catheter. “Our Center of Excellence for Balloons & Balloon Catheters in Athens has a long history of producing class-leading interventional products for our customers. The expansion will fuel our growth with best-in-class speed-to-market capabilities.”

The expansion increases the Athens campus to approximately 100,000 sq. ft. and includes an exterior refresh, additional engineering and lab space, manufacturing space and an employee break room. The Biomerics balloons and Interventional Advanced Catheter business operates out of three locations: Athens, TX; Brooklyn Park, MN; and Cartago, Costa Rica. Biomerics will celebrate the completion of the new campus expansion with a ribbon-cutting event today.

“The new building expansion in Athens Industrial Park is such a great demonstration of our partnership with Biomerics. They are a great corporate citizen and one of our largest employers. We are excited about the increase in investment, new jobs and what the future holds,” stated Joanie Ahlers, Director of Athens Economic Development Corporation.

“I am thrilled Biomerics continues to expand and reinvest in Athens,” Mayor Toni Clay said. “Here in Athens, we have some of the best talent in the nation. This makes our city and state a perfect fit for innovative companies like Biomerics. I look forward to seeing the continued growth and furthering our partnership for many years to come.”

“This investment says a lot about the performance of this team, our markets and our commitment to this community,” commented Travis Sessions, Chief Executive Officer of Biomerics. “We appreciate the support of the local community, state leaders and our many supply partners.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”